FDA seeks feedback on generative AI regulations - MedTech Dive
Reported by MedTech Dive · all stories from medtechdive.com
Editorial digest
The U.S. Food and Drug Administration is seeking public feedback. This input will help shape potential regulations for generative artificial intelligence. These regulations will specifically pertain to medical devices.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at MedTech Dive →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom8/18/2026
FDA seeks feedback on potential regulatory approaches for generative AI-enabled medical devices | AHA News - American Hospital Association
The FDA seeks input on regulating generative AI for medical devices.
- Trusted health newsroom11/3/2026
STAT+: FDA, CMS look to collaborate with states on health AI
Federal regulators at the FDA and CMS plan to partner with state authorities regarding medical artificial intelligence.
- Trusted health newsroom10/30/2026
STAT+: FDA, CMS scramble to avoid regulatory logjam as more states look to test AI in clinical settings
Federal health agencies are working quickly to prevent oversight bottlenecks as states prepare clinical artificial intelligence trials.
- Trusted health newsroom10/22/2026
STAT+: FDA finalizes its guidance on apps related to drugs, pharma rejoices
Federal regulators have completed formal guidelines for software applications paired with medications, drawing positive reactions from pharmaceutical manufacturers.
- Trusted health newsroom10/22/2026
STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
Virtual clinics are providing off-label GLP-1 therapies for substance use disorders before receiving formal regulatory authorization.
- Trusted health newsroom11/12/2026
STAT+: New documents raise more questions about Medicare’s AI prior-authorization experiment
Newly surfaced records prompt growing scrutiny regarding Medicare's pilot initiative using artificial intelligence for coverage approvals.
